Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: A systematic review and meta-analysis

Medicine (United States)

Volumn 95, Issue 11, 2016, Pages

  Ni, Wentao ^a   Han, Yuliang ^b   Liu, Jie ^c   Wei, Chuanqi ^a   Zhao, Jin ^a   Cui, Junchang ^a   Wang, Rui ^a   Liu, Youning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b Department of Neurology   (China)

^c Department of Vascular and Endovascular Surgery ^*  (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; TIGECYCLINE; CARBAPENEM DERIVATIVE; MINOCYCLINE;

ARTICLE; BLOODSTREAM INFECTION; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL (TOPIC); DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ENTEROBACTERIACEAE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE INFECTION; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORTALITY; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT RESPONSE; VOMITING; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; COMBINATION DRUG THERAPY;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MINOCYCLINE; TIGECYCLINE;

EID: 84961990667     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000003126     Document Type: Article

References (44)

1. Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9:228-236.
2. Tzouvelekis LS, Markogiannakis A, Psichogiou M, et al. Carbapene-mases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev. 2012;25:682-707.
3. Munoz-Price LS, Poirel L, Bonomo RA, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis. 2013;13:785-796.
4. Ni W, Cai X, Wei C, et al. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Braz J Infect Dis. 2015;19:170-180.
5. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis. 2005;40:1333-1341.
6. Petrosillo N, Giannella M, Lewis R, et al. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art. Expert Rev Anti Infect Ther. 2013;11:159-177.
7. Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther. 2006;4:9-25.
8. Giamarellou H, Poulakou G. Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opin Drug Metab Toxicol. 2011;7:1459-1470.
9. Kmeid JG, Youssef MM, Kanafani ZA, et al. Combination therapy for Gram-negative bacteria: what is the evidence? Expert Rev Anti Infect Ther. 2013;11:1355-1362.
10. Falagas ME, Vardakas KZ, Tsiveriotis KP, et al. Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. 2014;44:1-7.
11. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical-e-pidemiology/oxford.asp. Accessed 22 Sep 2015.
12. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
13. Nguyen M, Eschenauer GA, Bryan M, et al. Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagn Microbiol Infect Dis. 2010;67:180-184.
14. Neuner EA, Yeh JY, Hall GS, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011;69:357-362.
15. Satlin MJ, Kubin CJ, Blumenthal JS, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimi-crob Agents Chemother. 2011;55:5893-5899.
16. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect. 2011;17:1798-1803.
17. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Che-mother. 2012;56:2108-2113.
18. Sánchez-Romero I, Asensio A, Oteo J, et al. Nosocomial outbreak of VIM-1-producing Klebsiella pneumoniae isolates of multilocus sequence type 15: molecular basis, clinical risk factors, and outcome. Antimicrob Agents Chemother. 2012;56:420-427.
19. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapene-mase-producing K pneumoniae: importance of combination therapy. Clin Infect Dis. 2012;55:943-950.
20. Capone A, Giannella M, Fortini D, et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect. 2013;19:E23-E30.
21. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP, et al. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacter-iaceae: a major clinical challenge. Clin Microbiol Infect. 2013;19:E72-E79.
22. Daikos GL, Tsaousi S, Tzouvelekis LS, et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014;58:2322-2328.
23. Huang SR, Liu MF, Lin CF, et al. Molecular surveillance and clinical outcomes of carbapenem-resistant Escherichia coli and Klebsiella pneumoniae infections. J Microbiol Immunol Infect. 2014;47:187-196.
24. Kontopidou F, Giamarellou H, Katerelos P, et al. Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options. Clin Microbiol Infect. 2014;20:O117-O123.
25. Papadimitriou-Olivgeris M, Marangos M, Christofidou M, et al. Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit. Scand J Infect Dis. 2014;46:642-648.
26. Brizendine KD, Richter SS, Cober ED, et al. Carbapenem-resistant Klebsiella pneumoniae urinary tract infection following solid organ transplantation. Antimicrob Agents Chemother. 2015;59:553-557.
27. Chang YY, Chuang YC, Siu LK, et al. Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escher-ichia coli in intensive care units: a nationwide multicenter study in Taiwan. J Microbiol Immunol Infect. 2015;48:219-225.
28. de Oliveira MS, de Assis DB, Freire MP, et al. Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins. Clin Microbiol Infect. 2015;21:179e1-7.
29. Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70:905-913.
30. Ji S, Lv F, Du X, et al. Cefepime combined with amoxicillin/ clavulanic acid: a new choice for the KPC-producing Klebsiella pneumoniae infection. Int J Infect Dis. 2015;38:108-114.
31. Katsiari M, Panagiota G, Likousi S, et al. Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit: molecular characterisation and treatment challenges. J Glob Anti-microb Re. 2015;3:123-127.
32. Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70:2133-2143.
33. van Duin D, Cober E, Richter SS, et al. Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2015;70:1203-1211.
34. Di Carlo P, Gulotta G, Casuccio A, et al. KPC-3 Klebsiella pneumoniae ST258 clone infection in postoperative abdominal surgery patients in an intensive care setting: analysis of a case series of 30 patients. BMC Anesthesiol. 2013;13:13.
35. Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K pneumoniae in intensive care unit. Clin Infect Dis. 2013;56:697-700.
36. Balandin Moreno B, Fernández Simón I, Pintado García V, et al. Tigecycline therapy for infections due to carbapenemase-producing Klebsiella pneumoniae in critically ill patients. Scand J Infect Dis. 2014;46:175-180.
37. Mouloudi E, Massa E, Piperidou M, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc. 2014;46:3219-3221.
38. Vardakas KZ, Matthaiou DK, Falagas ME, et al. Tigecycline for carbapenem-resistant Klebsiella pneumoniae infections in the intensive care unit. Infect Dis (Lond). 2015;47:751-753.
39. Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother. 2011;55: 1162-1172.
40. Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis. 2011;11:834-844.
41. Shen F, Han Q, Xie D, et al. Efficacy and safety of tigecycline for the treatment of severe infectious diseases: an updated meta-analysis of RCTs. Int J Infect Dis. 2015;39:25-33.
42. FDA. 2013. Drug safety announcement-tigecycline. FDA, Rockville, MD. Available at: http://www.fda.gov/Drugs/DrugSafety/ ucm369580.htm. Accessed 30 September 2015.
43. Paul M, Carmeli Y, Durante-Mangoni E, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Che-mother. 2014;69:2305-2309.
44. Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother. 2013;57:1756-1762.